TScan Therapeutics (TCRX) EBITDA Margin (2020 - 2026)
TScan Therapeutics' (TCRX) quarterly EBITDA Margin came in at 2967.31% in Q1 2026, down 129757.0% year-on-year from N/an in Q1 2025, and down 219.27% on a QoQ basis from 929.41% in Q4 2025.
TScan Therapeutics (TCRX) EBITDA Margin (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has 7 years of EBITDA Margin data on file, last reported at 2967.31% in Q1 2026.
- On a quarterly basis, EBITDA Margin fell 129757.0% year-over-year to 2967.31% in Q1 2026; TTM through Mar 2026 was 1408.73%, a 175114.0% increase from a year earlier, with the FY2025 full-year figure at 1315.38%, up 347230.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 2967.31%, down from 929.41% in the prior quarter.
- Over the last five years, EBITDA Margin for TCRX reached as high as 296.17% in Q4 2023 and fell as low as 6364.55% in Q2 2024.
- Historically, EBITDA Margin has averaged 1938.22% across 5 years, with a median of 929.41% in 2025.
- Across the five-year window, EBITDA Margin sank 558279 bps in 2024 and soared 510795 bps in 2025, its largest moves.
- Year by year, EBITDA Margin stood at 602.55% in 2022, then surged by 51 bps to 296.17% in 2023, then plunged by 1764 bps to 5520.6% in 2024, then soared by 83 bps to 929.41% in 2025, then plunged by 219 bps to 2967.31% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 2967.31% in Q1 2026, 929.41% in Q4 2025, and 1475.59% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | TScan Therapeutics | 100.59 Mn | -27.47 Mn | - | -2,967.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,967.31% |
| Dec 31, 2025 | -929.41% |
| Sep 30, 2025 | -1,475.59% |
| Jun 30, 2025 | -1,256.60% |
| Mar 31, 2025 | -1,669.74% |
| Dec 31, 2024 | -5,520.60% |
| Sep 30, 2024 | -3,109.82% |
| Jun 30, 2024 | -6,364.55% |
| Mar 31, 2024 | -5,542.93% |
| Dec 31, 2023 | -296.17% |
| Sep 30, 2023 | -636.69% |
| Jun 30, 2023 | -781.77% |
| Mar 31, 2023 | -392.12% |
| Dec 31, 2022 | -602.55% |
| Sep 30, 2022 | -492.95% |
| Jun 30, 2022 | -375.89% |
| Mar 31, 2022 | -535.02% |
| Dec 31, 2021 | -497.62% |
| Sep 30, 2021 | -656.80% |
| Jun 30, 2021 | -374.96% |